J.J. Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared on X:
“Today at CIC Saint-Louis, a patient with myelofibrosis started for the 1st time in Europe a treatment with an anti-mutant CALR bispecific antibody.”
Source: J.J. Kiladjian/X